Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%
Market cap
$3.6B
P/E
29.9×
Fwd P/E
45.1×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

88.03 50.12 29.02 40.78
P/S ratio
5.46 6.40 4.73 8.36
P/FCF ratio
27.52 26.13 16.49 28.30
P/Operating CF
60.38 62.92 72.75 102.49
P/B ratio
2.15 2.53 1.91 3.38
EV/Sales
4.72 5.60 3.92 7.50
EV/EBITDA
52.96 38.17 22.14 34.00
EV/FCF
23.81 22.88 13.68 25.39
Current Ratio
6.23 8.15 9.31 9.16
Net Debt/EBITDA
(13.31) (9.87) (15.99) (17.91)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
1.14% 2.00% 3.45% 2.45%
Free Cash Flow Yield
3.63% 3.83% 6.06% 3.53%
Free Cash Flow per Share
0.53 0.62 0.41 0.54
Book value per Share
15.98 16.66 16.90 17.36
Free Cash Flow
41.97 48.80 32.25 42.97
EV/EBIT
94.46 50.15 27.41 39.84
Other line items

Show all line items

Columns are period end dates